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Abstract: 
Background: Vaccine antigens targeting specific P. falciparum parasite stages are under pre-clinical and clinical development. It 
seems plausible that vaccine with multiple specificities will offer higher protection. With this hypothesis, we exploited the Spy-
Tag/SpyCatcher conjugation system to make a, post expression, dual antigen conjugate vaccine, comprising two clinically tested 
antigen candidates (CSP and VAR2CSA). 
Methods: The DBL1x-DBL2x-ID2a region of  VAR2CSA was genetically fused with SpyTag at N-terminus. The full-length 
CSP antigen was genetically fused to C-terminal SpyCatcher peptide. The covalent interaction between SpyTag/SpyCatcher 
enables the formation of  DBL1x-DBL2x-ID2a:CSP conjugate vaccine. Immunogenicity and quality of  antibody responses in-
duced by the conjugate vaccine, as well as a control CSP-SpyCatcher vaccine, was tested in BALB/c mice. 
Results: Serum samples obtained from mice immunized with the conjugate vaccine were able to recognize both untagged 
DBL1x-DBL2x-ID2a as well as CSP antigen. Moreover, the geometric mean anti-CSP antibody titer was 1.9-fold higher in se-
rum (at day 35 and 55 post-first immunization) from mice immunized with the conjugate vaccine, as compared to mice receiving 
the control vaccine. 
Conclusion: The data obtained in this study serves as proof-of-concept for the simultaneous induction of  antibodies directed 
against individual antigen components in a dual stage anti-malaria vaccine.  
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Introduction
Plasmodium falciparum malaria remains a major public health 
problem as it continues to claim hundreds of  thousands 
of  lives globally each year. Pregnant women and children 
under 5 years of  age, living in sub-Saharan Africa are 
the most affected groups1. Individuals acquire immuni-
ty as a function of  malaria exposure2. Several measures 
have been taken by WHO to fight the disease, such as 
the use of  long-lasting insecticide-treated  nets (LLINs), 
indoor residual sprays (IRS) as well as anti-malarial drugs, 
which includes artemesinin-based combination therapies 
(ACTs)1. However, none of  these, or combinations here-
of, have achieved elimination of  the disease. A goal has 
been set by WHO to reduce malaria mortality by 90% in 
the year 20301, and in the absence of  an effective vaccine 
candidate it might be difficult to fulfill that goal on time.
Development of  effective anti-malaria vaccines has been 
hindered by the complexity of  the parasite’s life cycle as 
well as lack of  complete knowledge concerning the inter-
actions between the P.falciparum and host immune system, 
including mechanisms which regulate immune patholo-
gy in semi-immune individuals2. RTS,S/AS01 is the most 
advanced malaria vaccine candidate in terms of  clinical 
development. The vaccine consists of  a genetic fusion 
between the circumsporozoite protein (CSP) and a hep-
atitis B surface antigen embedded in lipid particles and 
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formulated with monophosphoryl lipid-A and Saponin. 
The fusion protein thus forms a virus-like particle (VLP) 
presenting a truncated form of  CSP. The native CSP is 
expressed on sporozoites and thus the vaccine targets 
the pre-erythrocytic stage of  the parasite. A recent large 
phase III clinical trial reported an efficacy of  37% protec-
tion in infants (6 – 12 weeks)3 and 47% in children (5 – 15 
months)4. However, widespread scale up of  RTS,S/AS01 
vaccination has not yet been finally endorsed by WHO 
partly due to the fast waning of  protective anti-CSP an-
tibodies1.  
VAR2CSA is a candidate vaccine antigen for preven-
tion of  pregnancy-associated malaria (PAM). PAM is a 
special syndrome caused by sequestration of  infected 
erythrocytes (IE) in the placenta, which can lead to poor 
pregnancy outcomes and death of  both the mother and 
foetus5,6. The sequestration is mediated by the interac-
tion between the human receptor condroitin sulphate A 
(CSA)7 and VAR2CSA expressed by CSA binding parasite 
isolates8. Women in malaria endemic regions acquire pro-
tective circulating anti-VAR2CSA antibodies as a function 
of  parity9, and protection is mediated by the ability of  
these antibodies to block the binding between CSA and 
VAR2CSA, thus preventing sequestration of  IEs in the 
placenta10. Similarly, the VAR2CSA-based vaccine aims 
to target CSA-binding blood-stage parasites and prevent 
their accumulation in the placenta. However, VAR2CSA 
is a 350 kDa antigen, which is made up of  6 Duffy bind-
ing-like domains (DBL) and 3 interdomain (ID) regions11. 
The size and complexity nature of  VAR2CSA makes an 
expression of  the full-length antigen a challenge for large 
scale expression, which is necessary for human clinical 
trial purposes. Therefore, it has been a strategy to de-
sign a vaccine based on only the CSA binding region of  
VAR2CSA12,13. Recently, two VAR2CSA candidate vac-
cines based on an N-terminal sub-fragment containing 
the minimal CSA binding region (ID1-DBL2x-ID2a)13 
have gone into phase I trial in human volunteers.
It is reasonable to assume that a malaria vaccine target-
ing multiple stages of  the parasite’s life cycle will have 
increased efficacy. Such multistage vaccines are ideally 
constructed as genetic fusions to avoid multiple produc-
tions and stability testing. VAR2CSA is a complex pro-
tein with many cysteines forming disulfide bonds and it 
would require extensive experimental effort to produce 
a fusion construct to another complex malaria antigen. 
Furthermore, fusion of  two antigens might lead to dom-
inant epitopes directing the response towards one of  
the antigens and thereby not inducing the desired mul-
tistage protective response. To examine if  this would be 
the case, we constructed a dual antigen conjugate malaria 
vaccine targeting both the pre-erythrocytic stage of  the 
parasite as well as the blood-stage of  placental malar-
ia infection. The two vaccine antigens (i.e. Full-length 
CSP and DBL1x-DBL2x-ID2a) were covalently linked, 
post-expression, by use of  the (SpyTag/SpyCatcher) 
split-protein conjugation system (also can be termed as 
bacterial superglue)14. This allows us to produce the an-
tigens separately to ensure quality and folding. The dual 
antigen conjugate vaccine was tested in BALB/c mice 
in parallel with a control vaccine consisting of  unfused 
CSP antigen. The titer of  anti-DBL1x-DBL2x-ID2a and 
anti-CSP antibodies, respectively, was compared in mice 
immunized with the two vaccines to examine whether the 
co-valent conjugation of  the two antigens had an effect 
on the immunogenicity of  the CSP antigen component. 
Also the recognition of  native VAR2CSA expression on 
IEs by the vaccine-induced anti-DBL1x-DBL2x-ID2a 
antibodies as well as anti-CSP antibodies from DBL1x-
DBL2x-ID2a:CSP conjugate and CSP-SpyCatcher vac-
cine respectively, was assessed by flow cytometry. The 
study serves as a proof  of  concept for simultaneous in-
duction of  antibodies against DBL1x-DBL2x-ID2a and 
CSP as a combined antigen. Future development of  the 
vaccine would combine dual stage antigen linkage with 
VLP-display15.
Methods
Design, expression and purification of  VAR2C-
SA-SpyTag antigen
The DBL1x-DBL2x-ID2a region of  VAR2CSA antigen 
from FCR3 genotype (Gene ID: 814364) was designed 
with C-terminally linked hexa-histidine purification tag 
(HIS), as well as SpyTag at the N-terminal15. A flexi-
ble linker made of  serine/glycine was inserted between 
SpyTag and DBL1x-DBL2x-ID2a antigen. BamHI and 
NotI restriction site was introduced on SpyTag-DBL1x-
DBL2x-ID2a-HIS gene specifically at N- and C-terminus, 
respectively. The sequences were codon optimized and 
synthesized by GeneArt® Life Technologies (Germany), 
before cloning and expression in baculovirus transfected 
Spodoptera frugiperda (Sf9) insect cells as described previ-
ously by15,16. For recombinant expression, Sf9 cells were 
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co-transfected with linear BakPak viral DNA (BD Biosci-
ences) and pAcGP67A/SpyTag-DBL1x-DBL2x-ID2a-
HIS plasmid DNA using Lipofectamine 2000 Reagent 
(Invitrogen, 11668–019). Then transfected cells were 
subsequently incubated at 28°C for 3-5 days, and high-tit-
tered recombinant baculovirus was harvested from the 
supernatant and used for High-Five cells infection. The 
induction took place for 2 days, and was followed by cen-
trifugation of  cells (at 8000g, 4°C, 10 min), collection 
and filtering of  the supernatant by 10kDa NMWC PES 
membranes (0.45 μm) (56-4112-04; GE Healthcare). The 
supernatant was later diafiltrated six times on an ÄKTA 
cross-flow (GE Healthcare) and loaded on a 1-ml HisSe-
lect column (H8286, Sigma-Aldrich) using an ÄKTA-ex-
press purification system (GE-Healthcare). Elution of  
the bound protein was performed using PBS buffer + 
200 mM imidazole (HisSelect), and lastly loaded directly 
onto a size exclusion chromatography HiLoad Superdex 
200PG (28-9893-35, GE Healthcare). Vivaspin 20 col-
umns were used to concentrate the monomeric peak (28-
9323-60, GE Healthcare).
Design, expression and purification of  CSP-Spy-
Catcher antigen
Sequences coding a hexa-histidine purification tag was 
added at the 5 prime end of  a construct coding a close to 
the full-length CSP sequence of  amino acids 25–383 (in 
the native molecule amino acids 1-24 contains a N-ter-
minal signal peptide and the sequence down-stream to 
383 contains a C-terminal GPI-anchor sequence) derived 
from the 3D7 isolate (Gene ID: 814364), whereas DNA 
coding the SpyCatcher sequence was added at the 3 prime 
end17. A flexible linker made of  Glycine-Glycine-Serine 
amino acids was inserted between the CSP and SpyCatch-
er sequence. HIS-CSP-SpyCatcher gene was later modi-
fied to contain the BamHI and NotI restriction site at N- 
and C-terminus, respectively, and codon-optimized for 
synthesis (GeneArt® Life Technologies, Germany). The 
gene was subsequently expressed in Trichoplusia ni insect 
cells, as described previously by15,18.
Conjugation of  CSP-SpyCatcher and SpyTag-
DBL1x-DBL2x-ID2a antigen
CSP-SpyCatcher antigen (Fig. 1b) was conjugated to a 
SpyTag-DBL1x-DBL2x-ID2a antigen (Fig. 1a) by mixing 
of  the two antigens in a molar ratio of  1:1 followed by 
overnight incubation at 4°C. The reaction took place in 
a standard PBS buffer supplemented with 0.2% polysor-
bate 80, with the PH value of  7.2. Mixing of  the two 
constructs resulted in an efficient conjugation facilitated 
by the SpyTag/SpyCatcher interaction, which creates an 
isopeptide bond, and hence the formation of  DBL1x-
DBL2x-ID2a:CSP conjugate (Fig. 1c).
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Mouse immunization
Female BALB/c mice (8 weeks old) (Taconic, Denmark) 
were immunized intramuscularly with 100 µl of  either 
DBL1x-DBL2x-ID2a:CSP or CSP-SpyCatcher vaccine 
(i.e. 5 μg antigen dose) on days 0, 21 and 42. Both vac-
cines were formulated with Alum 1 hour prior to the im-
munizations. Mice sera were collected on days 0, 14, 35, 
49 and 55, and anti-DBL1x-DBL2x-ID2a and anti-CSP 
antibodies were measured by ELISA using untagged (i.e. 
no SpyTag or SpyCatcher) DBL1x-DBL2x-ID2a and 
CSP as capturing antigens.
Antibody response measured by standard ELISA
Standard enzyme-linked immunosorbent assay (ELISA) 
was used to measure mice serum Ig levels as described 
previously by15. In short, the recombinant DBL1x-
DBL2x-ID2a protein (without SpyTag) or full-length 
CSP (without SpyCatcher) was coated (2 µg/ml in PBS) 
on a 96-well plate (Nunc MaxiSorp) by an overnight in-
cubation at 4oC. Plates were blocked with 1 % BSA buf-
fer at room temperature (RT) for 1 hour. 1:100 diluted 
mouse serum was then added in threefold dilutions to the 
wells, in triplicate, and was incubated for 1 hour at RT. 
Plates were washed three times in PBS with 0.05 % tween 
20 between individual steps. A 1:3000 dilution in block-
ing buffer of  Horseradish peroxidase (HRP)-conjugated 
polyclonal goat anti-mouse IgG (Life Technologies, Den-
mark) was added and incubated for 1 hour. Color reac-
tions were developed for 7 min by adding O-phenylenedi-
amine (OPD) (DAKO, Denmark) substrate. Termination 
of  HRP enzymatic reaction was completed by adding 2.5 
M H2SO4 and the optical density (OD) was measured 
by an ELISA plate reader (VersaMax Molecular Devic-
es) at 490 nm. The arbitrary cutoff  value of  OD490=0.2 
was used to determine the serum Ig endpoint titres. The 
geometric mean titres of  anti-CSP antibodies were cal-
culated both in mice sera derived from DBL1x-DBL2x-
ID2a:CSP conjugate as well as CSP-SpyCatcher vaccine. 
Spytag-DBL1-DBL2x-ID2a & CSP-SpyCatcher conjugation 
1 2
Fig. 1 SDS-PAGE analysis of SpyTag-DBL1-DBL2x-ID2a as well as CSP-SpyCatcher antigen. a Reduced (lane 1) and non-reduced (lane 2) SDS-PAGE gel of SpyTag-
DBL1-DBL2x-ID2a antigen. The band shift indicate the disulfide bond formation, as well as the protein expressed well in baculovirus expression system. On the gel
a total of 12 ul sample was loaded, and dilution buffer was used to adjust end concentration into 2 μg. The size of the band correspond to 118 kDa. b Non-reduced
(lane 1) and reduced (lane 2) SDS-PAGE gel of CSP-SpyCatcher antigen. No band shift is seen for CSP-SpyCatcher as it contain fewer cycteines for the disulfide
bonds as well as band shift formation. The protein expressed as soluble in the baculovirus expression system, and again the dilution buffer was used to adjust end
concentration (2 μg) in the total of 12 ul sample loaded on the gel. The theoretical size of CSP-SpyCatcher is 52 kDa but on the SDS-gel it was seen as 72 kDa. C The
DBL1-DBL2x-ID2:CSP conjugate formed after overnight incubation (at 4°C) of SpyTag-DBL1-DBL2x-ID2a and CSP-SpyCatcher antigen (lane 1 top). Equal molar
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Non-parametric, two tailed, Mann–Whitney Rank Sum 
Test statistical analysis was performed, and the P-value 
equivalent or less than 0.05 was regarded as statistically 
significant.
P. falciparum cultures
Parasite cultures were performed as described previously 
by19. In short, maintenance of  parasite culture was done 
in RPMI 1640 medium (Sigma Aldrich) mixed with 5% 
hematocrit of  human blood group O+ blood. The RPMI 
medium was enhanced by the addition of  0.125 µg/ml 
Albumax II (Invitrogen),  2% norm al human serum, 
25 mmol/liter sodium bicarbonate (Sigma Aldrich), and 
0.125 µg/ml gentamicin. The selection of  parasites for 
VAR2CSA expression was achieved by repeatedly pan-
ning of  IEs on decorin (D8428, Sigma Aldrich) coated 
on the bottom of  the culture flask. A day before the ex-
periment 0.5 ml of  a sterile solution of  4 µg/ml decorin 
(D8428, Sigma Aldrich) was prepared in Dulbecco's PBS. 
The decorin solution was transferred to a culture flask 
by adding 0.5 ml in one separate spot on the bottom of  
the flask, and the spot circumference was marked with 
a marker pen. It was followed by incubation at 4oC for 
overnight, whereas next day the flask was subsequently 
blocked by the addition of  5 ml sterile 2% BSA (A7030, 
Sigma Aldrich) in RPMI medium, followed by incubation 
at 37oC for 2 hours. Afterwards the blocking medium 
was removed without allowing the spot to dry out, and 
5 ml of  parasite culture medium was transferred to the 
decorin coated flask and gased. The IEs were allowed to 
adhere at 37oC for 1 hour at a gyrotable. Then after para-
site culture was gently removed by washing with a heated 
(at 37oC) RPMI medium + gentamycin (RBC wash). The 
RBC washing was done by adding 3-5 ml of  RBC wash 
(not directly on the spots), and very gently a small an-
gle tilting of  the flask was made to allow the slow wash 
away of  unbound IEs. The medium with unbound eryth-
rocytes was gently removed, and this step was repeated 
until erythrocytes were no longer visible in the medium 
supernatant. A light microscope was used for confirming 
the IEs-binding in the area of  the spot, and not in the 
area outside the spots. 5 ml medium as well as 200 µl of  
blood (5% hematocrit of  human blood group O+) was 
transferred followed by gas. The cultures were screened 
for Mycoplasma and all tested negative. Also isolates were 
frequently genotyped for monitoring using MSP-2 as well 
as GLURP primers in a single PCR step.
Flow cytometry 
The reactivity to native VAR2CSA expressed on FCR3-in-
fected IEs was measured for antisera obtained from 
mice immunized with the dual antigen (DBL1x-DBL2x-
ID2a:CSP) conjugate vaccine by flow-cytometry, as previ-
ously described19. In brief, MACS purification of  parasite 
lines (FCR3) suspended in PBS+2%FBS was done to ob-
tain late trophozoite and schizont stages after the expo-
sure to a strong magnetic field. Aliquots of  50 µl (2x106 
IEs) of  each parasite line in a 96-well plate was exposed 
to 50 µl of  mice serum and 100 µl solution of  1:200 goat 
anti-mice FITC antibodies (Invitrogen, 629511) diluted 
in PBS+2%FCS (PH 7.2), and 20 µl of  1:50 (0.1 mg/
ml) ethidium bromide. Data from 5000 infected cells 
was acquired from a 50 µl of  sample volume in a FC500 
flow-cytometer (Beckman Coulter). Mean fluorescence 
intensities were subsequently analyzed using Winlist (Ver-
ity Software).
Results
Immunogenicity of  VAR2CSA:CSP and CSP-Spy-
Catcher vaccine
Antibodies in serum from mice immunized with both the 
dual antigen conjugate vaccine and the CSP-SpyCatch-
er vaccine reacted with untagged CSP antigen coated on 
ELISA plate (Fig. 2a), and full-bleed sera from mice im-
munized with the conjugate vaccine were also able to rec-
ognize untagged DBL1x-DBL2x-ID2a antigen (Fig. 2b). 
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Fig. 3 Geometric mean titres. GMT of  anti-CSP IgG antibodies in sera obtained from mice (n = 5) immunized at days  14, 35, 
49 and 55 with 5 μg of  DBL1x-DBL2x-ID2a:CSP (filled circles) or CSP-SpyCatcher (open triangles) formulated in aluminium 
hydroxide. Analyzed sera were obtained on days 14, 35, 49 and 55, respectively. The geometric mean titer of  sera obtained on day 
35 and 55 from the DBL1x-DBL2x-ID2a:CSP vaccination group (n = 5) was more than 1.9-fold higher than in sera obtained at 
the same time points from the CSP-SpyCatcher vaccination group. P-values based on Mann-Whitney Rank sum test were P=0.20 
and P=0.27, respectively.
Fig. 2 ELISA showing the amount of anti-CSP IgG in sera from mice immunized with 1 
DBL1x-DBL2x-ID2a:CSP or CSP-SpyCatcher. A. Anti-CSP IgG titers in sera (n = 5) 2 
obtained from mice immunized (prime-boost-boost) with 5 μg of either DBL1x-DBL2x-3 
ID2a:CSP (filled circles) or CSP-SpyCatcher (open squares), using Aluminium hydroxide as 4 
extrinsic adjuvant. B.  Anti-DBL1x-DBL2x-ID2a IgG in sera from mice (n = 5) immunized 5 
(prime-boost-boost) with 5 μg of the DBL1x-DBL2x-ID2a:CSP conjugate vaccine. The OD 6 
cut off value of 0.2 was used to determine endpoint titres. 7 
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The geometric mean endpoint titres of  anti-CSP antibod-
ies in the DBL1x-DBL2x-ID2a:CSP conjugate vaccine 
immunized group were slightly higher on days 35, 49 as 
well as 55 (Fig. 3), as compared to the CSP-SpyCatcher 
immunized group, but the difference was not statistical-
ly significant for any of  the days (p=0.20, p=0.27 and 
p=0.27 respectively). Furthermore, 1.9-fold higher an-
ti-CSP antibodies was observed both on day 35 and 55 in 
mice immunized with the conjugate vaccine as compared 
to the ones immunized with CSP-SpyCatcher vaccine, al-
though the P-values were not statistically significant.    
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Fig. 4 Flow cytometry. Reactivity of  sera obtained from mice (n = 5) immunized (prime-boost-boost) with 5 μg of  DBL1x-
DBL2x-ID2a: CSP (full circles) or CSP-SpyCatcher (open triangles) against native VAR2CSA (FCR3 genotype) expressed on the 
surface of  infected red blood cells. Control sera (pre-bleeds) is shown as (open squares). The geometric mean recognition values 
for the DBL1x-DBL2x-ID2a:CSP group ranged between 7 and 37 whereas that of  the CSP-SpyCatcher group ranged from 5 to 
9, and the difference between the groups was statistically significant (p=0.0079). In comparison, the negative control (pre-bleed) 
sera had the lowest geometric mean recognition values of  less than 5.
Recognition of  native VAR2CSA expressed on the 
surface of  the infected erythrocytes.
The FCR3 parasite line was selected for in-vitro CSA 
binding and VAR2CSA expression, and mature stage par-
asites were stained with sera from mice immunized with 
either the DBL1x-DBL2x-ID2a:CSP conjugate vaccine 
or CSP-SpyCatcher vaccine. All five mice sera raised from 
immunization with the DBL1x-DBL2x-ID2a:CSP conju-
gate vaccine gave rise to antibodies recognizing native 
VAR2CSA on the surface of  IEs with a geometric mean 
above the level of  CSP-SpyCatcher vaccine at the 1:10 
dilution (p=0.0079) (Fig. 4).
Discussion
We have tested a dual stage malaria vaccine candidate 
that targets both the pre-erythrocytic liver stage as well 
as VAR2CSA-expressing blood-stage parasites infect-
ing the placenta. The aim was to explore if  fusion (or 
in this case, conjugation) would affect the specificity of  
the induced antibody responses towards the two subunit 
antigens. We found that the dual VAR2CSA:CSP conju-
gate vaccine induced antibodies that reacted with both 
recombinant VAR2CSA and native VAR2CSA expressed 
by the FCR3 parasite line. In addition, the conjugate vac-
cine gave rise to anti-CSP antibodies at a level 1.9-fold 
higher than unconjugated CSP on days 35 and 55, how-
ever the P-values were not statistically significant, which 
could be explained by an insufficient number of  observa-
tions in our experiment. It is clear that it may not always 
be practical to produce a dual-antigen conjugate vaccines, 
but rather to include the individual antigens as separate 
entities in a single vaccine formulation. However, there 
may be cases where the immunogenicity of  a vaccine an-
tigen is improved by the covalent conjugation to another 
antigen. This is especially true for low-immunogenic anti-
gens e.g.peptides, which are generally too small to elicit a 
sufficient immune response. Therefore,  carrier proteins 
(e.g. bovine serum albumin, keyhole limpet hemocyanin 
or tetanus toxoid) that contain several epitopes have been 
used to stimulate T-helper cells, which subsequently facil-
itate the induction of  the B-cell response. Traditionally, 
such protein-protein/protein-peptide conjugations have 
been done by chemical cross-linking chemistries, which 
generally require amino acid modifications (typically 
addition of  a thiol group via a Cys side chain). Howev-
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er, the presence of  multiple reactive functional groups 
may prevent site-specific conjugation and may lead to 
aggregates20. Therefore, the SpyTag/SpyCatcher conju-
gation system represents a novel easy-to-use tool to en-
able site-specific covalent conjugation of  antigens and, 
in turn, enable comparison of  immune responses raised 
against individual antigens prior to and post-conjugation. 
Besides, genetic fusion of  the SpyTag/SpyCatcher rarely 
imposes a negative effect on the expression and folding 
of  the antigen15 although in this study we did not examine 
whether native epitopes were retained in the CSP-Spy-
Catcher antigen.
In spite of  many years of  exposure women living in malar-
ia endemic areas become susceptible to infection during 
pregnancy, indicating that naturally acquired protection 
against pre-erythrocytic parasite stages is not sufficient 
to protect these women. Vice versa, antibodies that target 
VAR2CSA are probably not protective in their own right 
rather synergising with semi-protective responses against 
the pre-erythrocytic and the merozoites stage, although 
such associations are inherently difficult to investigate. 
There are several candidate vaccines encompassing single 
antigens in on-going human clinical trials, including two 
VAR2CSA candidate vaccines based on the N-terminal 
sub-fragment containing the minimal binding region21. 
Clinical trials attempting to combine the pre-erythrocytic 
vaccines RTS/S-AS01 and ME-TRAP is likewise on-go-
ing22. However, other pre-clinical studies combining vac-
cines against multiple parasite stages have not yet reached 
clinical testing to our knowledge23,24. A dual or multi-spec-
ificity vaccine candidate could offer higher protection by 
decreasing both the number of  parasites released from 
the liver and the number of  parasites surviving in the 
blood. In addition, it appears increasingly important to 
induce responses that exceed what is acquired through 
natural infections22. As an example the RTS/S-AS01 vac-
cine induces many fold higher antibody levels than those 
found in serum of  individuals living in endemic areas, 
however the problem of  the vaccine appears to relate to 
its inability to induce sustained antibody responses. Novel 
vaccine technologies enabling presentation of  complex 
antigens on the surface of  the virus-like particles may 
be one way to increase the longevity of  a response15,17. 
Hopefully, an endeavour to test a multi-component vac-
cine encompassing the current most promising vaccines 
against sporozoites, merozoites and infected erythrocytes 
will be possible in the future through uniting multiple dif-
ferent malaria vaccine centres.
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